Latest Ratios: P/E Ratio -0.0x · EV/EBITDA 21.4x · ROE N/A. (2020–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $6M | $3M | $28M | $85M | $25M | $11M |
| Enterprise Value | $252M | $249M | $38M | $85M | $24M | $11M |
| P/E Ratio → | -0.03 | — | — | — | — | — |
| P/S Ratio | 0.02 | 0.01 | 5.02 | 93.43 | — | — |
| P/B Ratio | — | — | 4.14 | 8.37 | 15.59 | 0.08 |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.75 | 6.67 | 93.56 | — | — |
| EV / EBITDA | 21.38 | 21.13 | — | — | — | 57.67 |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 34.2% | 34.2% | 8.4% | -15.8% | — | — |
| Operating Margin | -3.1% | -3.1% | -160.8% | -735.2% | — | — |
| Net Profit Margin | -33.4% | -33.4% | -130.0% | -5722.2% | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | — | — | -86.4% | -884.5% | -6.7% | -0.0% |
| ROA | -93.1% | -93.1% | -24.9% | -348.2% | -6.3% | -0.0% |
| ROIC | -8.8% | -8.8% | -51.5% | -91.8% | -1.9% | — |
| ROCE | — | — | -47.5% | -101.9% | -2.5% | -0.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 2.15 | 0.26 | 0.08 | 0.00 |
| Debt / EBITDA | 20.97 | 20.97 | — | — | — | 0.65 |
| Net Debt / Equity | — | — | 1.36 | 0.01 | -0.60 | -0.00 |
| Net Debt / EBITDA | 20.90 | 20.90 | — | — | — | -1.10 |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -0.25 | -0.25 | -7.76 | -41.58 | -805.94 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.13 | 0.13 | 1.69 | 0.42 | 0.27 | 0.67 |
| Quick Ratio | 0.12 | 0.12 | 0.92 | 0.39 | 0.27 | 0.67 |
| Cash Ratio | 0.04 | 0.04 | 0.66 | 0.22 | 0.26 | 0.39 |
| Asset Turnover | — | 1.63 | 0.16 | 0.04 | — | — |
| Inventory Turnover | 98.23 | 98.23 | 0.82 | 2.25 | — | — |
| Days Sales Outstanding | — | 21.80 | 96.17 | 682.08 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 16.6% | 34.1% | 1.1% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 16.6% | 34.1% | 1.1% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $430864 | $3M | $2M | $3M | $1M |
Critical liquidity and dilution
According to current market data, Moolec trades at a P/S ratio of 0.02, which suggests that investors are heavily discounting the company's future biotech potential while assigning minimal value to the legacy soy-processing revenue stream that currently dominates the firm's consolidated financial statements and overall valuation.
The extremely low P/S multiple indicates that the market views the company's revenue as low-quality commodity income rather than high-margin biotech growth. Investors should monitor whether the valuation shifts as the company moves toward commercializing its molecular farming pipeline, as the current pricing appears to reflect a binary outcome scenario.
As reported in recent financial statements, Moolec's ROIC has consistently remained in negative territory, reaching -6.6% in 2024Q2, which indicates that the company is currently destroying shareholder value rather than compounding it as it attempts to scale its capital-intensive molecular farming research and development efforts.
The persistent negative returns on invested capital suggest that the company's current asset base is not yet generating sufficient returns to cover the cost of its R&D and operational overhead. This trend warrants further investigation into whether the company can achieve a positive ROIC before its existing capital reserves are fully exhausted.
Based on the provided financial data, Moolec's cash conversion cycle has been highly volatile, peaking at 1592 days in 2023Q4, which highlights significant challenges in managing inventory and accounts receivable within its legacy soy-processing operations compared to industry standards for efficient agricultural ingredient processors.
The extended cash conversion cycle suggests that the company is struggling to convert its inventory into cash, which exacerbates its liquidity constraints. Investors should monitor whether management can optimize these cycles, as the current inefficiency places additional pressure on the company's already strained cash position.
According to recent balance sheet disclosures, Moolec's debt-to-equity ratio has surged to 7.90 as of 2024Q2, a significant increase from historical levels that suggests the company is increasingly reliant on debt financing to sustain its operations amidst persistent net losses and limited internal cash generation.
The high leverage ratio, combined with negative interest coverage, indicates that the company faces substantial risk regarding its ability to service debt obligations. This financial structure appears to limit management's flexibility and increases the likelihood of further dilutive financing to meet near-term capital requirements.
The P/E ratio is the most commonly misapplied metric for Moolec, as the company's negative earnings and heavy R&D spending render traditional valuation multiples meaningless, effectively obscuring the underlying progress of its molecular farming pipeline and the potential value of its proprietary transgenic soybean intellectual property.
Analysts should instead focus on regulatory milestone attainment and protein expression levels as more accurate indicators of the company's long-term viability. Relying on P/E or other earnings-based ratios fails to capture the transition from a commodity-processing business to a high-growth biotech platform, leading to potentially flawed investment conclusions.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MLEC stock.
Moolec Science S.A.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Moolec Science S.A.'s current EV/EBITDA is 21.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 39.4x.
Based on historical data, Moolec Science S.A. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Moolec Science S.A. has 34.2% gross margin and -3.1% operating margin.
Moolec Science S.A.'s Debt/EBITDA ratio is 21.0x, indicating high leverage. A ratio above 4x may signal elevated financial risk.